Eli Lilly Becomes the First Drugmaker to Hit $1tn Valuation

Due to the expansive growth that has been witnessed in the weight-loss drug market, Eli Lilly has become the first drugmaker to hit $1tn valuation.

AstraZeneca, Biopharma Giant, Announces $2bn Investment in Maryland

AstraZeneca, the biopharma giant announces $2bn Investment in Maryland with a view to double its production capacity and manufacture rare disease products.

FDA Looks to Accelerate Biosimilar Drug Development

FDA has proposed new policies that will accelerate biosimilar drug development with a view to lower the costs for biosimilar agents for cancer, other diseases.

Onshoring of Drug Product Manufacturing to Massachusetts

In its continued advent to investing in the U.S, Moderna is onshoring drug product manufacturing to its Moderna Technology Center at Massachusetts.

400 Global Regulatory Manufacturing Approvals for Samsung Biologics

Due to its competitiveness in quality and consistency, Samsung Biologics has received an astounding 400 regulatory manufacturing approvals across the world.

Australian Biopharma to Expand US Plasma-Derived Therapies

CSL, the Australian-based biopharma company is planning to invest around $1.5bn in the U.S over the next 5 years to manufacture plasma-derived therapies.